Zahangir Alam (2017). Nano Formulations of Natural Compounds for Enhanced Delivery. Journal of Diseases, 4(1): 14-20. DOI: 10.18488/journal.99.2017.41.14.20
Natural products were always the key elements in ancient history that are promising to treat various diseases including cancer and prevent any health disorders. They have seen a breakthrough since they were used in cancer chemotherapy and prevention with selective phytochemicals. Fruits and vegetables contain nutrient constituents that are bioactive in disease states. Extensive in vitro and in vivo research data is available to prove their efficacy. While few compounds have successfully transitioned to the clinical trials, few of them are still facing problems due to their poor bioavailability and lack of targeting. The lack of efficacy in human studies can be attributed to the complexity of the biological system and complexity of food. In recent years, identification of molecular targets made it necessary to develop efficient formulations for delivery. Nano formulations such emulsions, nanoparticles and nano vesicles are few of the advancements that showed promising faith in natural product chemotherapy. This paper reviews few of the techniques employed for natural compound delivery which can be applied to various compounds.
Multifactorial Analysis of the Parameters for Immunity in Preterm Infants
E. P. McGreal, K. Hearne, and O. B. Spiller, "Off to a slow start: Under-development of the complement system in term newborns is more substantial following premature birth," Immunobiology, vol. 217, pp. 176-186, 2012. View at Google Scholar | View at Publisher
Y. C. Lee and S. J. Lin, "Neonatal natural killer cell function: Relevance to antiviral immune defense," Clinical and Developmental Immunology, vol. 2013, pp. 1-6, 2013. View at Google Scholar | View at Publisher
D. B. Lewis and C. B. Wilson, Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In: Infectious diseases of the fetus and Newborn, Klein JO, Maldonado Y, Nizet V, et al. (Eds), 7th ed. Philadelphia: Elsevier Saunders, 2011.
Y. Kai-Larsen, G. H. Gudmundsson, and B. Agerberth, "A review of the innate immune defence of the human foetus and newborn, with the emphasis on antimicrobial peptides," Acta Paediatrica, vol. 103, pp. 1000-1008, 2014. View at Google Scholar | View at Publisher
N.L. Aryayev , I.M. Shevchenko , H.M. El Mezewghi , N.V. Shevchenko (2017). Multifactorial Analysis of the Parameters for Immunity in Preterm Infants. Journal of Diseases, 4(1): 8-13. DOI: 10.18488/journal.99/2017.4.1/184.108.40.206
The multifactorial analysis of the immunity for the preterm infants,
born at 34-36 weeks gestation, has been performed. Three factors of the
external load, which were 55.71% of the power load, have been determined
with the method of principal components. As a result of the analysis,
we can come to the conclusion about the feasibility of the advanced
study, the parameters of the immune system for the preterm infants, are
as follows: The complement fractions, The circulating immune complexes,
T-lymphocytes, T-helper cells, B-lymphocytes, the immunoregulatory
index, and IgE.
This study is one of very few studies which have investigated parameter
of immunity for preterm infants, study of the relationship of balance
disorders and immune mechanisms in preterm infants will identify new
approaches to the diagnosis of the pathology for neonatal period
Development of Periodontitis after Antihelicobacter Therapy in Patients with Ulcer Disease
B. J. Marshall, Helicobacter pioneers: Firsthand accounts from the scientists who discovered helicobacters, 1892–1982. Australia: Victoria, 2002.
A. K. Butt, A. A. Khan, B. A. Suleman, and R. Bedi, "Randomised clinical trial of helicobacter pylori from dental plaque," British Journal of Surgery, vol. 88, pp. 206–208, 2001.
P. Malfertheiner, F. Megraud, M. Giguere, and M. Riviere, "Quadruple therapy with bismuth subcitrate potassium metronidazole, tetracycline, and omeprazole is superior to triple therapy with omeprazole, amoxicillin, and claritromycin in eradication of helicobacter pylori, DDW, Abstractbook," pp. 137-139, 2010.
Q. Sun, "High efficacy of 14-day triple therapybased, bismuth-containing quadruple therapy for initial H. pylori eradication," Helicobacter, vol. 15, pp. 233–238, 2010.
N. Hudson, W. G. Brydon, and M. A. Eastwood, "Successful H. pylori eradication incorporating a oneweek antibiotic regimen," Alimentary Pharmacology & Therapeutics, vol. 9, pp. 47–50, 1995.
V. Z. S. Veldhuyzen, R. N. Fedorak, and J. Lambert, "Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of helicobacter pylori positive, functional (Nonulcer) dyspepsia," American Journal of Gastroenterology, vol. 98, pp. 1963–1969, 2003.
N. Robakidze, "The condition of the oral cavity in helicobacter pylori-infected with different variants of the ulcer," Dis. Cand. Med. Sciences. SPb, vol. 2, 2000.
A. V. Borysenko and O. V. Linovitskaya, "The role of microbial associations and helicobacter pylori in the development of generalized periodontitis," Modern Dentistry, vol. 5, pp. 40-42, 2000.
R. Z. Urazova, N. S. Shamshudinov, and T. Y. Kazantseva, "The condition of the mucous membrane of the mouth and of periodontal tissue in children with gastroduodenal pathology associated with helicobacter pylori," Dentistry, vol. 1, pp. 20-22, 2001.
N. Zakharova, "Clarithromycin is a standard component of H. pylori therapy," Eksper and the Wedge of Gastroenterology, vol. 3, 2003.
N. Filatov, "The use of drugs of macrolides in the treatment of periodontal disease," Dis. Cand. Med. Sciences M., pp. 18-39, 1997.
A. I. Grudanov and N. Starikov, "Medicines used in periodontal diseases," Periodontology, vol. 22, pp. 6-17, 1998.
L. A. Dmitrieva, Therapeutic dentistry vol. 2. Moscow, 2003.
N. M. Khomeriki and S. G. Khomeriki, "Influence of antisecretory and antacid on the sensitivity of the urease test in diagnosing helicobacter pylori infection," Farmateka, vol. 10, pp. 57-60, 2003.
S. A. Bulgakov, "Side effects during anti-helicobacter therapy," Almanac of the Wedge. Med., vol. 14, pp. 20-23, 2006.
L. V. Kudryavtseva, "The state of antibiotic resistance of helicobacter pylori in experimental and the wedge of gastroenterology," vol. 7, p. 7, 2003.
V. N. Tsarev and R. V. Ushakov, "Antimicrobial therapy in dentistry. M," vol. 2, p. 143, 2004.
T. L. Lapina, "Modern therapeutic method of ulcer disease: New drug," presented at the VIII Russian National Congress titled Human and Remedy. 2001. 5 Apr. Russia, 2001.
I. G. Balabanova, T. V. Tursina, and V. Y. Balabanov, "On the relationship of periodontal disease with gastroduodenal and hepatobiliary pathology at persons of young age," in Modern Trends in Gastroenterology (Proc. Dokl. Scientific.-Practical. Conf. 20-21 APR. 1995). Izhevsk, 1995, pp. 11-12.
A. I. Grudanov and I. V. Bezrukova, "Idiopathic lesions of the periodontium, with progressive bone lysis," Periodontology, vol. 6, pp. 19-22, 2000.
E. O. I, I. M. Rabinovich, and N. Razzhivina, "Dmitrieva N. Imudona application in complex treatment of dysbacteriosis of the oral cavity. Inflammatory diseases of the mucous membrane of the pharynx, the oral cavity and periodontium," Scientific Review of Solvay Pharma, Acad., vol. 2, pp. 27-29, n.d.
M. A. Manvelova, V. V. Cheshev, and N. G. Plyasunova, "Medical aspects of the microbe. The ecologist. Collected works of mniiem them. Gabrichevskogo, Ed. by B. A. Shenderov. M," vol. 5, pp. 18-26, 1991.
A. I. Grudanov, N. A. Dmitrieva, and E. V. Fomenko, "The use of probiotics in complex treatment of inflammatory periodontal diseases. M," Acad. Publish, vol. 3, 2006.
G. M. Pichkhadze, V. P. Rusanov, and V. E. Novoselov, "Antagonistic activity eubiotiki Maxilin to wound infection and its effect on the resistance of microorganisms to antibiotics," Dentistry, vol. 4, pp. 22-27, 2000.
V. N. Tsarev, L. A. Dmitrieva, and N. Filatova, "Experience of application rulid, sumamed and macropen in complex treatment of generalized periodontitis in the acute stage," Stomatology, vol. 76, pp. 4-9, 1997.
A. I. Grudanov, L. A. Dmitrieva, and Y. M. Maksimovskiy, "Periodontics: Current status, issues and directions of scientific researches," Periodontics, vol. 3, pp. 5-7, 1998.
Shokhsanam Khurramova , Bekhzod Abdullaev (2017). Development of Periodontitis after Antihelicobacter Therapy in Patients with Ulcer Disease. Journal of Diseases, 4(1): 1-7. DOI: 10.18488/journal.99/2017.4.1/220.127.116.11
Helicobacter pylori infection is associated with the most common
diseases of the stomach and duodenum such as peptic ulcer, gastric
cancer, and chronic gastritis. Stomach and duodenum are well-conditioned
organs for bacteria. Oral cavity is considered a secondary reservoir of
H. pylori. The infection responds well to complex antibacterial
treatment, but the risk of recurrence and side effects of this treatment
is sufficiently high. This article discusses the H.pylori-related
pathology of oral cavity and paradentium, and the side effects and
tolerability of eradication therapy. The pathways for optimization of
the treatment for H. pylori infection with the use of drugs contributing
to the restoration of microflora of the gastrointestinal tract and oral
cavity are offered.
All authors contributed equally to this work. This study was one of few
studies, which have investigated affecting antimicrobial and
anti-ulcerative drugs to the development of periodontitis. Authors
declare that there is found relations between pathogenesis of
periodontitis and treatment of peptic ulcer disease.